Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo, +20

New England Journal of Medicine

Genotypic and Phenotypic Characterization of HIV-1 Patients with Primary Infection

Tuofu Zhu, Hongmei Mo, Ning Wang, +4

Science

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Graham R. Foster, Nezam H. Afdhal, Stuart K. Roberts, +32

New England Journal of Medicine

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

Akhteruzzaman Molla, Marina Korneyeva, Qing Gao, +14

Nature Medicine

Viral ReplicationOrdered AccumulationNatural SciencesHuman RetrovirusPathogenesis +8

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Eric Lawitz, Fred Poordad, Phillip S. Pang, +6

The Lancet

HepatologyHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy +6

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, +28

The Lancet Infectious Diseases

HepatologyHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy +6

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Eric Lawitz, Jay Lalezari, Tarek Hassanein, +26

The Lancet Infectious Diseases

HepatologyHepatitis CGenotypes 1Viral HepatitisAntiviral Drug Development +8

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes

Sergio Borgia, Charlotte Hedskog, Bandita Parhy, +8

The Journal of Infectious Diseases

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

Martin Markowitz, Hongmei Mo, Dale J. Kempf, +4

Journal of Virology

ImmunologyMolecular BiologyRelative Drug ResistancePharmacotherapyAntiviral Drug +15

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

Evguenia S. Svarovskaia, Hadas Dvory‐Sobol, Neil Parkin, +19

Clinical Infectious Diseases